Hepatitis A vaccine

Hepatitis A vaccine
Havrix junior monodose (hepatitis A) for children
Vaccine description
TargetHepatitis A virus
Vaccine typeInactivated or attenuated
Clinical data
Trade namesHavrix, others
AHFS/Drugs.comMonograph
MedlinePlusa695003
Pregnancy
category
  • AU: B2
Routes of
administration
Intramuscular
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • US: ℞-only
  • EU: Rx-only
  • In general: ℞ (Prescription only)
Identifiers
DrugBank
ChemSpider
  • none
UNII
 NY (what is this?)  (verify)

Hepatitis A vaccine is a vaccine that prevents hepatitis A. It is effective in around 95% of cases and lasts for at least twenty years and possibly a person's entire life. If given, two doses are recommended beginning after the age of one. It is given by injection into a muscle. The first hepatitis A vaccine was approved in the European Union in 1991, and the United States in 1995. It is on the World Health Organization's List of Essential Medicines.

The World Health Organization (WHO) recommends universal vaccination in areas where the disease is moderately common. Where the disease is very common, widespread vaccination is not recommended as people typically develop immunity through infection during childhood. The US Centers for Disease Control and Prevention (CDC) recommends vaccinating:

  • All children aged 12–23 months
  • Unvaccinated children and adolescents aged 2–18 years
  • International travelers
  • Men who have sex with men
  • People who use injection or non-injection drugs
  • People who have an occupational risk for infection
  • People who anticipate close contact with an international adoptee
  • People experiencing homelessness
  • People with HIV
  • People with chronic liver disease
  • Any person wishing to obtain immunity

In addition, a person who has not previously received hepatitis A vaccine and who has direct contact with someone with hepatitis A should get hepatitis A vaccine within two weeks after exposure.

Severe side effects are very rare. Pain at the site of injection occurs in about 15% of children and half of adults. Most hepatitis A vaccines contain inactivated virus while a few contain weakened virus. The ones with weakened virus are not recommended during pregnancy or in those with poor immune function. A few formulations combine hepatitis A with either hepatitis B or typhoid vaccine.

Soreness or redness where the shot is given, fever, headache, tiredness, or loss of appetite can happen after receiving the hepatitis A vaccine. As with any medicine, there is a very remote chance of a vaccine causing a severe allergic reaction, other serious injury, or death.